A股異動 | 中藥股集體上漲 中醫藥管理局稱新冠本土感染者普遍應用了中醫藥
格隆匯12月20日丨中藥股集體大漲,其中隴神戎發,維康藥業,紫鑫藥業,佛慈制藥,盤龍藥業,濟川藥業漲停,羚鋭製藥漲8%,新光藥業,健民集團漲7%;港股白雲山,同仁堂國藥漲月3%,中國中藥漲1%。消息面上,國家中醫藥管理局在16日的新聞發佈會上稱,新冠肺炎疫情發生以來,目前,新冠肺炎本土確診病例和無症狀感染者中,除個別特殊情況人員外,均普遍應用了中醫藥。中醫藥治療在改善患者臨牀症狀等方面發揮了重要作用。國家中醫藥管理局應對新冠肺炎疫情防控工作領導小組專家組副組長張忠德介紹,專家組經過綜合分析研判認為,本輪疫情仍屬於中醫“疫病”範疇,中醫的核心病因病機沒有大的改變,還是屬於濕毒鬱閉,中醫藥為主治療仍然有效。


Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.